<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00492076</url>
  </required_header>
  <id_info>
    <org_study_id>E04/05/PP-M</org_study_id>
    <nct_id>NCT00492076</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma</brief_title>
  <official_title>A Randomised, Double-Blind Placebo-Controlled Study Assessing the Short-Term Effect of a Dermatophagoides Pteronyssinus Extract, Quantified in Mass Units, in Subjects With Perennial Mite Induced Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ALK-Abelló A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ALK-Abelló A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a short course of subcutaneous
      immunotherapy is efficacious in mite induced asthma. The efficacy is based on reduction in
      control medication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The control of mild-moderate persistent asthma include the need of concomitant medication, as
      inhaled corticosteroids. However, compliance in perennial asthma is low. The aim of this
      study is to assess the possibility to reduce the need of concomitant medication through a
      short-course of subcutaneous immunotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in inhaled corticosteroids</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in symptoms and rescue medication Tolerability</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Allergic Asthma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pangramin Plus Dermatophagoides pteronyssinus 100%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Pangramin Plus placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pangramin Plus D. pteronyssinus 100%</intervention_name>
    <description>Active. Pangramin Plus D. pteronyssinus 100%
Placebo. Pangramin Plus placebo</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mild/moderate persistent asthma

          -  Positive skin prick test or specific IgE to mites

          -  Age: 14-55 years old

        Exclusion Criteria:

          -  Immunotherapy contraindications

          -  Allergy to other inhalant allergens

          -  Previous immunotherapy (5 years)with mites
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ana I Tabar, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Virgen del Camino</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Virgen del Camino, Allergology Service</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2007</study_first_submitted>
  <study_first_submitted_qc>June 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2007</study_first_posted>
  <last_update_submitted>October 15, 2008</last_update_submitted>
  <last_update_submitted_qc>October 15, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2008</last_update_posted>
  <responsible_party>
    <name_title>Fernando de la Torre/medical marketing manager</name_title>
    <organization>ALK-ABELLO, S.A.</organization>
  </responsible_party>
  <keyword>Specific immunotherapy</keyword>
  <keyword>Mite</keyword>
  <keyword>Asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

